@SjsmithStuarti
iAccount based inUnited Kingdom
About this account
- Account based in
- United Kingdom
- Connected via
- United Kingdom App Store
Account-level information from X, not a live location or the device used for a specific post.
Joined March 2015
- Tweets245
- Following353
- Followers155
- Likes158
Stuart Smith retweeted
Radiotherapy after surgery halves risk of recurrence in a type of brain tumour that can often grow back, trial shows.
Find out more in The Lancet: spkl.io/60137TUFS #EANO2026
Stuart Smith retweeted
🇬🇧 A “revolutionary” new procedure at London’s St Thomas’ Hospital can identify the cause of an infection with a single test, potentially within hours instead of days.
Using an Oxford Nanopore GridION, it sequences genetic material in a patient sample and searches simultaneously for bacteria, viruses and fungi.
For critically ill patients, that could mean finding the infection and choosing the right treatment far faster, while reducing unnecessary use of broad-spectrum antibiotics.
It's not yet clear when the test could be made widely available, but it's the first step of a massive shift in the efficiency of diagnosing health issues everywhere.
Writer: Mhedi
New tech can identify illness with just one test
Correspondence: Clinical Long-Read Genome Sequencing for Rare-Disease Diagnostics nej.md/4e03ejh
#Genetics
In a trial involving children with Chiari type I malformation and syringomyelia, the percentage with surgical complications did not differ significantly between posterior fossa decompression with duraplasty and decompression alone. Full trial results and Research Summary: nej.md/3RtZTQR
ALT This image is from a Research Summary published in the New England Journal of Medicine about decompression with or without duraplasty for Chiari I and syringomyelia. It includes a diagram of the brain highlighting Chiari I and syringomyelia, information about study participants, and images comparing two groups: PFD with duraplasty and PFD alone. Participants included 162 children with an average age of 10 years; 54% are noted as female, and 46% as male. The images indicate the sample sizes for each group: 78 for PFD with duraplasty and 84 for PFD alone. A prompt invites readers to view the full Research Summary at NEJM.org.
Stuart Smith retweeted
Correspondence: Toward Same-Day Genome Sequencing in the Critical Care Setting nej.md/4qg4KlE
#ASHG25 | @GeneticsSociety
Stuart Smith retweeted
Traditional brain tumour characterisation requires a battery of tests, delaying critical treatment decisions. Discover how Oxford Nanopore sequencing streamlines this with a single, rapid assay to provide high-confidence tumour methylation profiling. nanoporetech.com/application…
Stuart Smith retweeted
Our winner of the Young Investigator Award 2025 is Phoebe McCrorie. Congratulations!
Thank you to Karen Noble at Brain Tumour Research for supporting this alongside BNOS.
Photo - Karen Noble, Phoebe McCrorie, Susan Short. #BNOS2025
Stuart Smith retweeted
A breakthrough moment in brain infections.
Faced with a mystery infection, Judith Breuer sequenced a biopsy sample—and identified a pathogen never before linked to brain infections. Find out more. #NanoporeConf
Stuart Smith retweeted
Why wait weeks for a diagnosis?
Danny Miller discusses the future potential of Oxford Nanopore sequencing, and how clinicians could get actionable results within hours—not days or weeks. No need to batch samples. Same-day sequencing, same-day answers. #NanoporeConf
Stuart Smith retweeted
In the studio, Matt Loose shares how: “Surgeons were literally knocking, saying I’ve got a patient today. Once people see what’s possible, they start to believe it — and get excited.” when talking about his new CNS tumour profiling method.
Stuart Smith retweeted
Knowledge is power. In the studio, Matt Loose shared insights on rapid CNS profiling — and how one participant told him: “Even if the answer isn’t what you want, it’s better than not knowing at all.”
Stuart Smith retweeted
Real time rapid prediction of acute leukemia via methylation profiles with @nanopore using #Marlin @DanaFarber #LondonCalling2025
Stuart Smith retweeted
Great news about a new test that reduces diagnosis time for certain types of brain tumour. This highlights the importance of continued research to improve earlier diagnosis and faster detection for the less survivable cancers.
bbc.co.uk/news/articles/cpvk…
Stuart Smith retweeted
An ultra-rapid method of genetically diagnosing brain tumours has been developed, cutting the classification time from 6-8 weeks, to as little as two hours. This could remove uncertainty those face waiting weeks for their diagnosis and prognosis. Read more:bit.ly/43EbUXh
Stuart Smith retweeted
Groundbreaking research from scientists @mattloose from @UoNLifeSci @UoNFacultyMHS & Medics @NUHMedicine means brain tumours could be diagnosed in as little as 2 hours using technology from @nanopore
Read the full story ▶️ ow.ly/h2vc50VW7mL
Stuart Smith retweeted
The future is now.
In this webinar, Prof. Matt Loose showcases a revolutionary tool, ROBIN, that uses Oxford Nanopore technology for rapid and comprehensive molecular profiling of central nervous system tumours.
Watch the webinar here: bit.ly/3REqZSd
Stuart Smith retweeted
From weeks to hours.
Prof. Matt Loose shares a transformative tool (ROBIN) that uses Oxford Nanopore technology to rapidly and comprehensively classify central nervous system tumours in this webinar.
Watch here to discover what’s possible: bit.ly/42FRV9g
Stuart Smith retweeted
Proud to support #ShineALight for Brain Tumour Awareness Month & @braintumourrsch - one in three of us know someone with a brain tumour (I lost a great mate, Miles, to glioblastoma recently) yet only 1% of the UK’s cancer research spend goes into them.
This must change.
Stuart Smith retweeted
Congrats to @SjsmithStuart and Dr Simon Paine for winning the #NIHAwards Innovation award for work on bringing @nanopore sequencing into the clinic for rapid brain tumour diagnosis.
Sadly a similar experience already occurs for many brain tumour patients. Radical change needed as the number of patients across all cancers needing these tests increases rapidly
Great piece in @Daily_Express at the weekend on the need for reduced turnaround times for genomic testing in lung cancer: express.co.uk/news/uk/196743………
@Roy_Castle_Lung
@NHSEngland
@BTOGORG
@DRBLUNGS
@LungConsultant
@rintoul_robert
@thelucyjohnston
@DHSCgovuk